European Biopharmaceutical Review |
 |
|
|
|
|
 |
| |
|
|
|
|
|
If Only... 2020 In Review: The Value of Unified Regulatory Information Management
David Gwyn at Amplexor
The pandemic highlighted much about life science companies’ operational limitations, particularly around the way they manage and make use of regulatory information. It’s worth reflecting on how pharmaceutical organisations coped with the disruption of the last year and how this might inform ongoing digital transformation plans
|
|
|
|
Mental Health is Vital to Our Economic Recovery
Pierluigi Antonelli at Angelini Pharma
The coronavirus pandemic has had a detrimental impact in many areas of day-to-day life. One of these is mental health, which has been overlooked for far too long and should not continue to be sidelined any longer
|
|
|
|
You, Me, and the Two Cs
Andrew Newland at ANGLE plc
We are all aware of the unprecedented impact of COVID-19 on individual health and wellbeing, global healthcare systems, and economies; but what impact has COVID-19 had on cancer diagnosis and care?
|
|
|
|
IDMP – The Year in Review and Looking Ahead to 2021
Remco Munnik at Iperion Life Sciences Consultancy
Standing at the beginning of a new year, it’s a perfect time to highlight European progress with IDMP developments during 2020, and look ahead to what to expect this year
|
|
|
|
Amplified Needs Accelerate Innovation During a Pandemic
Patrick Schneider at Merck
COVID-19 has given the life science industry the opportunity to evolve and meet global demand, but can these advancements, and the lessons learned, help us stay ahead of the next worldwide health crisis?
|
|
|
|
|
|
The Role of Eosinophils and Their Impact on Patients
As our understanding of eosinophils progresses, they are increasingly recognised as key biomarkers across a range of diseases. EBR spoke to Dr Jonathan Steinfeld at GlaxoSmithKline about the importance of eosinophils and how they can impact patients with a number of different conditions
|
|
|
|
Targeting the Root Cause of Inflammatory Gastrointestinal Diseases
Daniel Vitt and Jessica Breu at Immunic
A promising new approach for restoring the intestinal barrier function could pave the way for more influential treatments to help those who suffer from diseases such as IBD, IBS, or coeliac disease
|
|
|
|
Understanding the Burden of Eczema Around the World
Matthew Shaulis at Pfizer
Patients suffering with atopic dermatitis, more commonly known as eczema, require therapies to ease the burden of what can be a painful and life-altering condition
|
|
|
|
|
|
The Role of ddPCR in Developing Safe and Effective AAV-Based Gene Therapies
Mark White at Bio-Rad
There are a number of bioprocessing hurdles AAV developers must overcome to insure the generation of a safe and effective product. Luckily, there are also a number of technological solutions that can help face these challenges
|
|
|
|
Safety Testing for C&G Therapy Products
Claudia Benati, Liesbeth Hameetman, Luca Benedan, Giulia Rovaris, Mary David, and Dr Jonathan Demick at Eurofins BioPharma Product Testing
Available technologies for rapid testing offer possibilities for quick delivery of the genetically modified product for diseases that have long been considered incurable
|
|
|
|
The Challenges of AAV-Based Gene Therapy
Dr Hüseyin Besir and Dr Dana Holzinger at PROGEN
A lack of suitable and widespread reference material in gene therapy is just one of the many obstacles facing laboratories around the world attempting to find treatments for genetic diseases
|
|
|
|
|
|
How COVID-19 is the Catalyst for a Digital Revolution in Healthcare
Mellissa Flowerdew-Clarke at Dept
The ongoing global pandemic has brought into sharp focus many of the pharmaceutical industry’s pitfalls in the areas of technology and innovation. Luckily, the process to address these weaknesses has already begun
|
|
|
|
Masks, Gloves, and the Power of a Better Idea: A Brief History of PPE
Jon Weisberg
The ascendance of COVID-19 has recently brought the value of effective PPE into a worldwide spotlight, and examining the history of all the equipment we take for granted today might provide us with further clarity as to its necessity
|
|
|
|
AI Solutions During a Crisis
EBR sits down with the Novartis Foundation’s Dr Ann Aerts to discuss the role of AI in the current pandemic, and how it can be a catalyst for change in the future fight against global health crises
|
|
|
|
Fast-Tracking Digital Innovation During Critical Times
Lorenzo Vasini at Paragon DCX
The pharmaceutical sales rule book has been torn up in the last year. Void of the biggest sales channel, face-to-face meetings, sales teams are seeking new means to engage the healthcare industry
|
|
|
|
|
Managing the Challenges of Manufacturing ADCs
Nicolas Camper at Abzena
With nine FDA-approved ADCs, this emerging class of biopharmaceuticals is changing the landscape of oncology treatments, but bringing an ADC to market requires complex manufacturing expertise and coordination between small molecule and biologics teams
|
|
|
|
Biosimilars – Transforming Global Patient Access to Treatments
Gabriela Marton at Arriello
Biosimilars provide cost-effective alternatives to biological drugs and represent a growing opportunity. However, Europe lacks a harmonised regulatory approach
|
|
|
|
Making the Right Choices for Reliable HCP Monitoring by ELISA
Martin Föge and Stefan Sommerschuh at BioGenes
The clearance of biopharmaceutical drugs from host cell protein (HCP) impurities during manufacturing remains a constant challenge, necessitating the reliable monitoring of their removal from the final drug product. The ELISA is the broadly accepted gold standard for HCP monitoring. Important steps for customised HCP ELISA development will be discussed
|
|
|
|
How to Optimise Process Quality of Liquid Tube Systems
Fernando Rangel at SONOTEC
Optimisation of liquid tube systems can be achieved in single-use bioprocessing applications by means of ultrasonic technologies
|
|
|
|
The Antimicrobial Susceptibility Testing Conundrum
Dr Lauren Laing and Dr Giles Sanders at TTP
Antimicrobial susceptibility testing at the point of care could slow the spread of antimicrobial resistance, but only creative technology development and regulatory equivalence data will unlock this prize
|
|
|
|
|
|
